Application 219241
- Type
- ANDA
- Sponsor
- AUROBINDO PHARMA LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OXCARBAZEPINE | OXCARBAZEPINE | TABLET, EXTENDED RELEASE;ORAL | 150MG | No | No |
| 002 | OXCARBAZEPINE | OXCARBAZEPINE | TABLET, EXTENDED RELEASE;ORAL | 300MG | No | No |
| 003 | OXCARBAZEPINE | OXCARBAZEPINE | TABLET, EXTENDED RELEASE;ORAL | 600MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A219241-001 | OXCARBAZEPINE | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | ||
| A219241-002 | OXCARBAZEPINE | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | ||
| A219241-003 | OXCARBAZEPINE | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A219241-001 | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A219241-002 | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A219241-003 | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219241-001 | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219241-002 | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A219241-003 | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A219241-001 | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A219241-002 | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A219241-003 | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | 6a471c1ec25d… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219241-001 | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219241-002 | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A219241-003 | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE / ORAL | 2025-04-30 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OXCARBAZEPINE | OXCARBAZEPINE | REMEDYREPACK INC. | ffc8d10c-0049-4fe5-beb8-79cc6a197ede | 2026-07-23 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| OXCARBAZEPINE | OXCARBAZEPINE | REMEDYREPACK INC. | b571ee0f-3c2a-4c55-9c2b-e00014e2ec7a | 2026-07-21 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | Cardinal Health 107, LLC | 3e0f8d9f-7659-4524-8f93-6200314356c8 | 2026-07-21 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | ANI Pharmaceuticals, Inc. | 867eaf99-3e31-4f75-bfae-2898804d956d | 2026-07-13 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| OXCARBAZEPINE | OXCARBAZEPINE | REMEDYREPACK INC. | 85a9bdee-4d10-4097-ae3d-0bf8d844a11b | 2026-07-08 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | American Health Packaging | c0f9df3f-280e-4394-8d7e-ad04803b2635 | 2026-07-02 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| OXCARBAZEPINE | OXCARBAZEPINE | Major Pharmaceuticals | b1d54def-057d-4608-bc8f-1d967ac3ec91 | 2026-06-15 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| oxcarbazepine | OXCARBAZEPINE | Zydus Lifesciences Limited | e23d8a74-b47b-462a-b09c-90bdd58a032e | 2026-06-13 | Warnings, Adverse reactions | oxcarbazepine OXCARBAZEPINE |
| oxcarbazepine | OXCARBAZEPINE | Zydus Pharmaceuticals (USA) Inc. | 5048dc87-2d89-434d-be51-4a97b0ce0601 | 2026-06-13 | Warnings, Adverse reactions | oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | REMEDYREPACK INC. | c7718f8b-63e2-40b9-b519-e687cfc2cacf | 2026-06-11 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | REMEDYREPACK INC. | 188a48ad-c412-416a-b15b-de5f232740a2 | 2026-06-11 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | REMEDYREPACK INC. | 0abe9478-4084-286d-e063-6294a90a9ba7 | 2026-06-10 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| OXCARBAZEPINE | OXCARBAZEPINE | REMEDYREPACK INC. | fcf5044a-8cfd-47d5-9f47-8f6674843c24 | 2026-06-08 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | Sun Pharmaceutical Industries, Inc. | 7ecd5eef-46f4-407f-9b63-ba65adb3eced | 2026-06-03 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| OXCARBAZEPINE | OXCARBAZEPINE | Camber Pharmaceuticals, Inc. | a18f591b-587e-4769-8ac2-9cfba0b82526 | 2026-05-22 | Warnings, Adverse reactions | OXCARBAZEPINE OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | ASCLEMED USA INC. | c42b2cb2-8b45-488b-bf63-81909a1f06cb | 2026-05-19 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | NCS HealthCare of KY, LLC dba Vangard Labs | a14b5756-4fd1-4ba7-bc23-e1fa9212a148 | 2026-05-18 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | Coupler LLC | 512ab25c-ea79-1e59-e063-6294a90ae9a0 | 2026-05-06 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | Umedica Laboratories USA Inc. | e46d4654-76bc-4c33-ac2b-e89ae11b7697 | 2026-05-05 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |
| Oxcarbazepine | OXCARBAZEPINE | Coupler LLC | 51008af2-39ac-546c-e063-6294a90a758f | 2026-05-04 | Warnings, Adverse reactions | Oxcarbazepine OXCARBAZEPINE |